CompletedNot Applicable

A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older

South Korea641 participantsStarted 2021-08-23

Plain-language summary

A prospective, open, observational study to confirm the lipid-lowering effect, changes in glucose metabolism, and safety after 6 months of administration of atostazet to hypercholesterolemic patients 65 years of age or older

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males or females aged ≥ 65 years * Primary Hypercholesterolemia * moderate risk or higher patient based on Korean Guidelines for the Management of Dyslipidemia (the 4th edition) Exclusion Criteria: * Patients with a known hypersensitivity to any of the major or minor components of the study drug * Patients with active hepatic disease or unexplained persistently elevated serum aminotransferase levels * Patients with myopathies * Patients receiving glecaprevir and pibrentasvir

What they're measuring

Incidence of Adverse events

Timeframe: 24 weeks to the base

Trial details

NCT IDNCT07489183

SponsorDong Wha Pharmaceutical Co. Ltd.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-09-07

View on ClinicalTrials.gov More Hypercholesterolemia trials